HOME >> BIOLOGY >> NEWS
Commercialization deal boosts hope for new sickle-cell drug

A novel once-a-day treatment for sickle-cell disease, based on technology developed at Children's Hospital Boston (CHB) and Beth Israel Deaconess Medical Center (BIDMC), has taken an important step toward the clinic. McNeil Consumer & Specialty Pharmaceuticals and Icagen, Inc., a private biotechnology company, have agreed to jointly develop and commercialize the drug, known as ICA-17043. The agreement follows successful Phase II clinical trials in 90 adults with sickle-cell disease. The companies will collaborate on multicenter Phase III trials, the final step before seeking marketing approval from the U.S. Food and Drug Administration.

Current treatment options are few for sickle-cell disease, a genetic blood disorder that affects millions of children and adults worldwide, including about 70,000 Americans, primarily people of African descent (about 8 percent of African-Americans are carriers). The only approved sickle-cell treatment, developed at CHB 20 years ago, is hydroxyurea. Companies have been slow to invest in additional sickle-cell treatments because the potential market is relatively small. The FDA granted ICA-17043 Orphan Drug Designation in 2000 and Fast Track Status in 2002.

ICA-17043 is related to clotrimazole, an antifungal drug approved in 1975 and long used to treat vaginal yeast infections, jock itch, and athlete's foot. A team led by Dr. Carlo Brugnara, director of the Hematology Laboratory at CHB, discovered in the early 1990s that clotrimazole also reduces sickling of red blood cells.

In sickle cell disease, the body produces an abnormal form of hemoglobin, the compound in red blood cells that carries oxygen. The hemoglobin clumps up and polymerizes forms long rod shapes. This polymerization bends the red cells into sickle-shaped structures, and also causes the cell to lose water. This dehydration, in turn, hardens the cells and promotes sickling by hastening polymerization.

"When
'"/>

Contact: Mary-Ellen Shay
mary.shay@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
3-Aug-2004


Page: 1 2 3

Related biology news :

1. EC boosts European electron microscopy research
2. Bioreactor boosts chemical fermentation by 50 percent: study
3. New genomics tool boosts diabetes research
4. DHEA boosts growth rate of human neural stem cells
5. Marine scientists discover nutrient pollution boosts fungi, bacteria killing Caribbean reefs
6. Sleep boosts ability to learn language, University of Chicago researchers find
7. $13 million grant boosts breast cancer research
8. New national studies show combined hormone replacement therapy boosts stroke, dementia
9. Green tea boosts antimicrobial properties of toothpaste
10. Study boosts confidence in potential screening tool for Alzheimers disease
11. Twenty years of monkey research boosts AIDS knowledge

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... 2017 , ... We are proud to announce the successful ... Dilworth, MN site. The inspection took place Monday, July 31st through Friday, August ... a routine Bioresearch Monitoring Program (BIMO) with the USFDA wherein multiple Dermatology Vasoconstriction ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kapstone Medical is proud ... successes helping medical technology companies and inventors develop and safeguard their latest innovations. ... engineering firm with a portfolio of clients in the United States and around the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, ... modular downlights designed to stay tightly sealed and perform efficiently for years. The ... wet location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; ...
(Date:8/14/2017)... Ca (PRWEB) , ... August 14, 2017 , ... ... poorly characterized and performing antibodies. Key researchers in the antibody community have recently ... characterization and consistency for antibodies in the laboratory. , The team ...
Breaking Biology Technology:
Cached News: